Cancer. 2011 Apr 28. doi: 10.1002/cncr.26164. [Epub ahead of print],

Prevalence of complementary medicine use in a phase 1 clinical trials program: The MD Anderson Cancer Center Experience.

Abstract

A key end point of early cancer clinical trials is the assessment of toxicities and their possible association with new experimental drugs. Therefore, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies seen in a dedicated phase 1 clinic was evaluated.

If you have any questions about the website, please notify the This email address is being protected from spambots. You need JavaScript enabled to view it.